Literature DB >> 25038228

Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling.

Neil C Robson1, Laura Hidalgo2, Angeles Vicente2, Alberto Varas2, Tristan Mc Alpine3, Heng Wei3, Víctor G Martínez2, Ana Entrena2, Gustavo J Melen4, Andrew S MacDonald5, Alexander Phythian-Adams5, Rosa Sacedón2, Eugene Maraskovsky6, Jonathan Cebon3, Manuel Ramírez4.   

Abstract

Natural killer (NK) cells are critical for innate tumor immunity due to their specialized ability to recognize and kill neoplastically transformed cells. However, NK cells require a specific set of cytokine-mediated signals to achieve optimal effector function. Th1-associated cytokines promote effector functions that are inhibited by the prototypic Th2 cytokine IL4 and the TGFβ superfamily members TGFβ1 and activin-A. Interestingly, the largest subgroup of the TGFβ superfamily are the bone morphogenetic proteins (BMP), but the effects of BMP signaling on NK cell effector functions have not been evaluated. Here, we demonstrate that blood-circulating NK cells express type I and II BMP receptors, BMP-2 and BMP-6 ligands, and phosphorylated isoforms of Smad-1/-5/-8, which mediate BMP family member signaling. In opposition to the inhibitory effects of TGFβ1 or activin-A, autocrine BMP signaling was supportive to NK cell function. Mechanistic investigations in cytokine and TLR-L-activated NK cells revealed that BMP signaling optimized IFNγ and global cytokine and chemokine production, phenotypic activation and proliferation, and autologous dendritic cell activation and target cytotoxicity. Collectively, our findings identify a novel auto-activatory pathway that is essential for optimal NK cell effector function, one that might be therapeutically manipulated to help eradicate tumors. Cancer Res; 74(18); 5019-31. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25038228      PMCID: PMC4167038          DOI: 10.1158/0008-5472.CAN-13-2845

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Induction of Smad6 mRNA by bone morphogenetic proteins.

Authors:  M Takase; T Imamura; T K Sampath; K Takeda; H Ichijo; K Miyazono; M Kawabata
Journal:  Biochem Biophys Res Commun       Date:  1998-03-06       Impact factor: 3.575

Review 2.  Promiscuity and specificity in BMP receptor activation.

Authors:  Thomas D Mueller; Joachim Nickel
Journal:  FEBS Lett       Date:  2012-03-08       Impact factor: 4.124

3.  Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.

Authors:  Gin-Ah Song; Hyun-Jung Kim; Kyung-Mi Woo; Jeong-Hwa Baek; Gwan-Shik Kim; Jin-Young Choi; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

4.  Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor.

Authors:  A Hata; G Lagna; J Massagué; A Hemmati-Brivanlou
Journal:  Genes Dev       Date:  1998-01-15       Impact factor: 11.361

5.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.

Authors:  S G M Piccirillo; B A Reynolds; N Zanetti; G Lamorte; E Binda; G Broggi; H Brem; A Olivi; F Dimeco; A L Vescovi
Journal:  Nature       Date:  2006-12-07       Impact factor: 49.962

6.  Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.

Authors:  Roberta Castriconi; Claudia Cantoni; Mariella Della Chiesa; Massimo Vitale; Emanuela Marcenaro; Romana Conte; Roberto Biassoni; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-19       Impact factor: 11.205

7.  Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line.

Authors:  L A Fernandez; B Pope; C Lee; E Zayed
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

8.  Novel regulators of bone formation: molecular clones and activities.

Authors:  J M Wozney; V Rosen; A J Celeste; L M Mitsock; M J Whitters; R W Kriz; R M Hewick; E A Wang
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

9.  The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells.

Authors:  Massimo Vitale; Mariella Della Chiesa; Simona Carlomagno; Chiara Romagnani; Andreas Thiel; Lorenzo Moretta; Alessandro Moretta
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

Review 10.  From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines.

Authors:  Jacques Banchereau; Virginia Pascual; Anne O'Garra
Journal:  Nat Immunol       Date:  2012-09-18       Impact factor: 25.606

View more
  9 in total

1.  Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.

Authors:  Jenna H Newman; David J Augeri; Rachel NeMoyer; Jyoti Malhotra; Elaine Langenfeld; Charles B Chesson; Natalie S Dobias; Michael J Lee; Saeed Tarabichi; Sachin R Jhawar; Praveen K Bommareddy; Sh'Rae Marshall; Evita T Sadimin; John E Kerrigan; Michael Goedken; Christine Minerowicz; Salma K Jabbour; Shengguo Li; Mary O Carayannopolous; Andrew Zloza; John Langenfeld
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

Review 2.  Immunoregulation by members of the TGFβ superfamily.

Authors:  WanJun Chen; Peter Ten Dijke
Journal:  Nat Rev Immunol       Date:  2016-11-25       Impact factor: 53.106

3.  An Integrated Immune-Related Bioinformatics Analysis in Glioma: Prognostic Signature's Identification and Multi-Omics Mechanisms' Exploration.

Authors:  Xin Fan; Lingling Zhang; Junwen Huang; Yun Zhong; Yanting Fan; Tong Zhou; Min Lu
Journal:  Front Genet       Date:  2022-05-03       Impact factor: 4.772

4.  Distinct CholinomiR Blood Cell Signature as a Potential Modulator of the Cholinergic System in Women with Fibromyalgia Syndrome.

Authors:  Christoph Erbacher; Shani Vaknine; Gilli Moshitzky; Sebastian Lobentanzer; Lina Eisenberg; Dimitar Evdokimov; Claudia Sommer; David S Greenberg; Hermona Soreq; Nurcan Üçeyler
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

5.  Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.

Authors:  Laura D Hover; Christian D Young; Neil E Bhola; Andrew J Wilson; Dineo Khabele; Charles C Hong; Harold L Moses; Philip Owens
Journal:  Cancer Lett       Date:  2015-07-30       Impact factor: 8.679

6.  The ferroptosis inducer erastin promotes proliferation and differentiation in human peripheral blood mononuclear cells.

Authors:  Ding Wang; Nan Xie; Wanli Gao; Rui Kang; Daolin Tang
Journal:  Biochem Biophys Res Commun       Date:  2018-07-24       Impact factor: 3.575

7.  Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.

Authors:  Herena Eixarch; Laura Calvo-Barreiro; Carme Costa; Gemma Reverter-Vives; Mireia Castillo; Vanessa Gil; José Antonio Del Río; Xavier Montalban; Carmen Espejo
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088

8.  The BMP Pathway Participates in Human Naive CD4+ T Cell Activation and Homeostasis.

Authors:  Víctor G Martínez; Rosa Sacedón; Laura Hidalgo; Jaris Valencia; Lidia M Fernández-Sevilla; Carmen Hernández-López; Angeles Vicente; Alberto Varas
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

Review 9.  Regulation of the Immune System in Health and Disease by Members of the Bone Morphogenetic Protein Family.

Authors:  Tommaso Sconocchia; Giuseppe Sconocchia
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.